Hypertriglyceridemia
The DOI matches its Crossref record, with a small difference in title or year; 50 of the 50 references it cites were found in a registry or an index.
Abstract
A healthy 45-year-old man is found on routine screening to have hypertriglyceridemia. He does not have diabetes, and he takes no medications. His father died at 55 years of age in an automobile accident, his mother is healthy at the age of 67 years, and he has two healthy older brothers. His body-mass index is 28. His fasting triglyceride level is 400 mg per deciliter, total cholesterol 230 mg per deciliter, LDL cholesterol 120 mg per deciliter, and HDL cholesterol 30 mg per deciliter. How should his case be assessed and managed?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To date, aside from icosapent ethyl, fish oil therapy has not been shown to prevent CV adverse events.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [370]
In the citing paper
“No RCT has yet been reported to investigate the benefit of reducing severe (>500 mg/dL) or moderate (>200 mg/dL) hypertriglyceridemia to prevent CVD.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [370]
In the citing paper
“Severe hyperchylomicronemia also occurs when a secondary cause of hypertriglyceridemia such as diabetes or pregnancy is superimposed on an underlying genetic defect (78).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [78]
In the citing paper
“FCHL is also strongly suggested by a positive personal or family history of premature atherosclerosis with hypertriglyceridemia (78).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [78]
In the citing paper
“It is important to distinguish FHTG, which seems to confer no risk of premature CVD, from FCHL, which is associated with a high incidence of premature CVD (78).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [78]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Hokanson, J. E., & Austin, M. A. (1996) · Journal of Cardiovascular Risk · doi:10.1097/00043798-199604000-00014 · Cited by 1,706
Alexander, C. M., Landsman, P. B., Teutsch, S. M., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1210 · Cited by 1,475
Goldstein, J. L., Schrott, H. G., Hazzard, W. R., Bierman, E. L., & Motulsky, A. G. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107332 · Cited by 1,443
Ross, R., Dagnone, D., Jones, P. J. H., Smith, H., Paddags, A., Hudson, R., & Janssen, I. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-2-200007180-00008 · Cited by 1,435
Lamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G. R., Lupien, P. J., & Despre´s, J.-P. (1997) · Circulation · doi:10.1161/01.cir.95.1.69 · Cited by 1,077
Lemieux, I., Pascot, A., Couillard, C., Lamarche, B., Tchernof, A., Alméras, N., Bergeron, J., Gaudet, D., Tremblay, G., Prud’homme, D., et al. (2000) · Circulation · doi:10.1161/01.cir.102.2.179 · Cited by 937
Metabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896
Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
Management of Dyslipidemia in Adults With Diabetes
Haffner, S. M. (1998) · Diabetes Care · doi:10.2337/diacare.21.1.160 · Cited by 786
Hooper, L., Thompson, R. L., Harrison, R. A., Summerbell, C. D., Ness, A. R., Moore, H. J., Worthington, H. V., Durrington, P. N., Higgins, J. P. T., Capps, N. E., et al. (2006) · BMJ · doi:10.1136/bmj.38755.366331.2f · Cited by 676
Non–High-Density Lipoprotein Cholesterol Level as a Predictor of Cardiovascular Disease Mortality
Cui, Y., Blumenthal, R. S., Flaws, J. A., Whiteman, M. K., Langenberg, P., Bachorik, P. S., & Bush, T. L. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.11.1413 · Cited by 658
Havel, P. J. (2005) · Nutrition Reviews · doi:10.1111/j.1753-4887.2005.tb00132.x · Cited by 607
Familial lipoprotein disorders in patients with premature coronary artery disease.
Genest, J. J., Martin-Munley, S. S., McNamara, J. R., Ordovas, J. M., Jenner, J., Myers, R. H., Silberman, S. R., Wilson, P. W., Salem, D. N., & Schaefer, E. J. (1992) · Circulation · doi:10.1161/01.cir.85.6.2025 · Cited by 596
Grundy, S. M. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1568 · Cited by 551
Elam, M. B., Hunninghake, D. B., Davis, K. B., Garg, R., Johnson, C., Egan, D., Kostis, J. B., Sheps, D. S., Brinton, E. A., & for the ADMIT Investigators (2000) · JAMA · doi:10.1001/jama.284.10.1263 · Cited by 517
Pischon, T., Girman, C. J., Sacks, F. M., Rifai, N., Stampfer, M. J., & Rimm, E. B. (2005) · Circulation · doi:10.1161/circulationaha.104.532499 · Cited by 514
Carr, M. C., & Brunzell, J. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0432 · Cited by 493
Self-citationEfficacy and safety of high-density lipoprotein cholesterol-increasing compounds
Birjmohun, R. S., Hutten, B. A., Kastelein, J. J. P., & Stroes, E. S. G. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.031 · Cited by 429
Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006
Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., Franklin, B., Kris-Etherton, P., Harris, W. S., Howard, B., et al. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000238352.25222.5e · Cited by 345
Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia
Brunzell, J. D., Albers, J. J., Chait, A., Grundy, S. M., Groszek, E., & McDonald, G. B. (1983) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38008-1 · Cited by 305
Self-citationMyocardial infarction in the familial forms of hypertriglyceridemia
Brunzell, J. D., Schrott, H. G., Motulsky, A. G., & Bierman, E. L. (1976) · Metabolism · doi:10.1016/0026-0495(76)90089-5 · Cited by 303
Self-citationEffects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a)
Maher, V. M. G. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530220037029 · Cited by 298
Clofibrate and niacin in coronary heart disease
(1975) · JAMA · doi:10.1001/jama.231.4.360 · Cited by 297
Austin, M. A., McKnight, B., Edwards, K. L., Bradley, C. M., McNeely, M. J., Psaty, B. M., Brunzell, J. D., & Motulsky, A. G. (2000) · Circulation · doi:10.1161/01.cir.101.24.2777 · Cited by 255
Self-citation(2001) · Medical Entomology and Zoology · Cited by 227
Self-citationHopkins, P. N., Heiss, G., Ellison, R. C., Province, M. A., Pankow, J. S., Eckfeldt, J. H., & Hunt, S. C. (2003) · Circulation · doi:10.1161/01.cir.0000081777.17879.85 · Cited by 207
Prescribing Exercise at Varied Levels of Intensity and Frequency: A Randomized Trial
Duncan, G. E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.20.2362 · Cited by 202
Effect of Weight Loss with Reduction of Intra-Abdominal Fat on Lipid Metabolism in Older Men
Purnell, J. Q. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.3.977 · Cited by 161
Phillips, N. R., Havel, R. J., & Kane, J. P. (1981) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.1.1.13 · Cited by 121
Meyers, C. D., Carr, M. C., Park, S., & Brunzell, J. D. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-12-200312160-00009 · Cited by 72
Self-citationWatanabe, H., Söderlund, S., Soro-Paavonen, A., Hiukka, A., Leinonen, E., Alagona, C., Salonen, R., Tuomainen, T.-P., Ehnholm, C., Jauhiainen, M., et al. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000209577.04246.c0 · Cited by 69
Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a)
Maher, V. M. G. (1995) · JAMA · doi:10.1001/jama.274.22.1771 · Cited by 48
FAMILIAL AGGREGATION OF CARDIOVASCULAR RESPONSE TO SUBMAXIMAL EXERCISE IN THE HERITAGE FAMILY STUDY
LEON, A. S., AN, P., RICE, T., P??russe, L., Gagnon, J., Wilmore, J. H., Skinner, J. S., Rao, D. C., & Bouchard, C. (2001) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200105001-01173 · Cited by 43
Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease
ZAMBON, A., BROWN, B. G., DEEB, S. S., & BRUNZELL, J. D. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01645.x · Cited by 38
Self-citationNocturnal Hypertriglyceridemia and Hyperinsulinemia Following Moderate Evening Intake of Alcohol
Taskinen, M., & Nikkilä, E. A. (1977) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1977.tb16807.x · Cited by 34
How Much and What Type of Physical Activity Is Enough?: What Physicians Should Tell Their Patients
Blair, S. N. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.20.2324 · Cited by 23
Research works printed but not linked: 4
- Brunzell JD, Deeb SS. Familial lipoprotein lipase deficiency, apo CII deficiency and hepatic lipase deficiency. In: Scriver CR, Beaudet AI, Sly WD, Valle D, eds. The metabolic and molecular bases of inherited disease. 8th ed. Vol. 3. New York: McGraw-Hill, 2000:2789-816.
- Brunzell JD, 1973, Trans Assoc Am Physicians, 86, 245
- Erkelens DW, 1980, J Hum Nutr, 34, 370
- 10.1001/jama.221.8.918 · doi:10.1001/jama.221.8.918
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
“diagnostic tests are warranted to test for the presence of familial hypertriglyceridemia or familial dysbetalipoproteinemia [11,136,138,144].”
Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk
Després, J.-P., Lemieux, I., Bergeron, J., Pibarot, P., Mathieu, P., Larose, E., Rodés-Cabau, J., Bertrand, O. F., & Poirier, P. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.159228 · Cited by 1,589
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
“The focus is on individuals with cardiometabolic risk, characterized by the clustering of central obesity, insulin resistance, dyslipidaemia, and hypertension, which together increase the risk of CVD and T2DM.18 The EAS Consensus Panel is well aware of uncertainties and controversies regarding triglycerides and HDL-C…”
Influential
Metadata
- Authors
- Brunzell, J. D.
- Affiliations
- University of Washington (US)
- Corresponding author
- Brunzell, John D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-06
- Volume
- 357
- Issue
- 10
- Pages
- 1009-1017
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2412988337
- Cited by
- 268
- References
- 49
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 7 · 2023: 5 · 2022: 6 · 2021: 14 · 2020: 11 · 2019: 9 · 2018: 11 · 2017: 13 · 2016: 16 · 2015: 13 · 2014: 18 · 2013: 18 · 2012: 25
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- hypertriglyceridemia, familial hypertriglyceridemia, dyslipidemia management, family history (medicine), cardiovascular risk assessment
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Apolipoproteins B, Cholesterol, Clofibric Acid, Combined Modality Therapy, Diet Therapy, Female, Humans, Male, Middle Aged, Niacin, Reference Values, Triglycerides, Hypertriglyceridemia, Weight Loss, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.